FDA Drug Safety Website Could Cause More Harm Than Good, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis says risk information should be communicated quickly, but that it should be validated first, to avoid confusion. Company's comments come on heels of FDA's statement that Novartis' Elidel should have a black box, a move the company describes as unsubstantiated by clinical evidence and experience.
You may also be interested in...
Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk
Novartis expects labeling negotiations will begin within the next few weeks and says a "black box" is unjustified. A medication guide will also be required for the eczema treatments, FDA says.
FDA Drug Watch Website Coming "Soon"
FDA's new drug safety website will make more information available to the public "soon," the website states as of Feb. 23
“Drug Watch” Website Included In FDA’s Rx Safety Reforms
FDA will launch a Drug Watch website as part of its drug safety reform initiative